NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Recro Pharma, Inc. (“Recro” or the “Company”) (NASDAQCM: REPH) violated federal securities laws.
Click here to learn about the case: http://www.wongesq.com/pslra-c/recro-pharma-inc. There is no cost or obligation to you.
On May 24, 2018, Recro revealed that the U.S. Food & Drug Administration (the “FDA”) had declined to approve Recro’s New Drug Application for the non-opioid pain relief treatment IV meloxicam. The FDA stated in its Complete Response Letter that the drug’s analgesic effects did not meet its expectations and raised questions related to certain data included in the NDA. Following this news, Recro stock fell 54.7% to close at $5.63 per share on May 24, 2018.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.